VRS 826
Alternative Names: polypeptide conjugated interleukin-1 receptor antagonist - Aravive; VRS-826Latest Information Update: 08 May 2024
At a glance
- Originator Aravive
- Developer Versartis
- Class Antihyperglycaemics; Peptides; Recombinant fusion proteins
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus